Phosphate

Nutrien Announces Release Dates for Fourth Quarter 2022 Results and Conference Call

Nutrien Ltd (TSX and NYSE: NTR) announced today plans to release fourth quarter earnings results on Wednesday, February 15, 2023, after market close. Nutrien will host a conference call the following day, Thursday, February 16, 2023 at 10:00 a.m. EST to discuss and answer investor questions on fourth quarter results and the outlook.

Investors can access the call by dialing 1-888-886-7786 or 1-416-764-8683. A webcast of the conference call number can be accessed by visiting Nutrien's website, https://www.nutrien.com/investors/events .

A recording of the conference call will be available after the completion of the call by dialing 1-877-674-7070 and inputting the conference identification number 345556#. The recording will be available through May 29, 2023.

About Nutrien

Nutrien is the world's largest provider of crop inputs and services, playing a critical role in helping growers increase food production in a sustainable manner. We produce and distribute approximately 27 million tonnes of potash, nitrogen and phosphate products world-wide. With this capability and our leading agriculture retail network, we are well positioned to supply the needs of our customers. We operate with a long-term view and are committed to working with our stakeholders as we address our economic, environmental and social priorities. The scale and diversity of our integrated portfolio provides a stable earnings base, multiple avenues for growth and the opportunity to return capital to shareholders.

Investor Relations
Jeff Holzman
Vice President, Investor Relations
(306) 933-8545

Media Relations
Megan Fielding
Vice President, Brand & Culture Communications
(403) 797-3015

Contact us at: www.nutrien.com

News Provided by Business Wire via QuoteMedia

NTR:CA,NTR
How to Invest in Phosphate (Updated 2023)

How to Invest in Phosphate (Updated 2023)

Discovering ways to invest in phosphate begins with understanding its primary uses. For example, 90 percent of phosphate is primarily used in the agriculture sector.

Because of its essential properties, and since there is no known substitute for it, phosphate can be found in fertilizer products all over the world as a way to aid plant growth. It is also used as a supplement in animal feed, as a food preservative and for several other chemical purposes.

As the world's population grows and demand for food increases, the need for phosphate fertilizer is only expected to increase. For that reason, some believe phosphate investing is compelling. Read on for a brief overview of the phosphate market, including supply and demand dynamics and investing options.

Keep reading...Show less

Spectrum Pharmaceuticals Provides Update on ROLVEDON Injection and Announces Unaudited Fourth Quarter 2022 Financial Results

-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million --

-- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024 --

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff

-- Commercial employee (non-executive) who was hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection is the recipient of this grant --

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on January 26, 2023, Spectrum's Board of Directors granted an aggregate of 20,833 inducement restricted stock units ("RSUs") to a commercial non-executive employee who was hired specifically for the launch of ROLVEDON. The award was granted under Spectrum's 2022 Employment Inducement Incentive Award Plan ("Inducement Plan") as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spectrum, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Spectrum, pursuant to Nasdaq Listing Rule 5635(c)(4).

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Spectrum Pharmaceuticals Announces Management Changes

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that Francois J. Lebel, M.D., Executive Vice President and Chief Medical Officer, will step down from his role to pursue other opportunities, effective immediately. The company's clinical development function will be led by Dr. Shanta Chawla, Vice President, Clinical Development, also effective immediately. Dr. Chawla was the principal physician on the ROLVEDON™ (eflapegrastim-xnst) injection Phase 3 program and was instrumental in successfully navigating the BLA submission that resulted in the drug's approval. Dr. Lebel will serve as a consultant to Spectrum through March 2023 to facilitate a seamless transition.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Spectrum Pharmaceuticals' ROLVEDON Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that ROLVEDON (eflapegrastim-xnst) has been added to the latest National Comprehensive Cancer Network® Supportive Care Guidelines (NCCN Guidelines) in oncology for Hematopoietic Growth Factors. The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN) and now include ROLVEDON as a treatment option under Management of Neutropenia: G-CSFs for Prophylaxis of Febrile Neutropenia and Maintenance of Scheduled Dose Delivery.

"We are pleased with the rapid inclusion of ROLVEDON in the NCCN guidelines as an appropriate option for cancer patients who are at risk for febrile neutropenia." said Tom Riga, President and Chief Executive Officer of Spectrum Pharmaceuticals. "The NCCN guidelines are a standard resource for determining the best course of treatment and supportive care for people living with cancer. The inclusion in the NCCN guidelines further reinforces the clinical profile of ROLVEDON and is an important milestone for the program."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff

-- Commercial employees (non-executive) who were hired specifically for the launch of ROLVEDON™ (eflapegrastim-xnst) injection are the recipients of this grant --

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on December 5, 2022, Spectrum's Board of Directors granted an aggregate of 736,988 inducement restricted stock units ("RSUs") to commercial non-executive employees who were hired specifically for the launch of ROLVEDON. The awards were granted under Spectrum's 2022 Employment Inducement Incentive Award Plan ("Inducement Plan") as employment inducement awards pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Spectrum, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Spectrum, pursuant to Nasdaq Listing Rule 5635(c)(4).

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×